Nabiximols (Sativex) approved in 30+ countries for MS spasticity
Multiple sclerosis is the condition with the second-strongest cannabinoid evidence base after epilepsy. Nabiximols (Sativex), a 1:1 THC:CBD oromucosal spray, is approved in over 30 countries for MS-related spasticity and neuropathic pain. Multiple RCTs demonstrate significant improvements in patient-reported spasticity, pain, and sleep disruption.
Medical Disclaimer: MS treatment requires specialist neurological care. Cannabinoids are adjunct treatments for symptom management, not disease-modifying therapies. Consult your neurologist before starting cannabinoids.
Multiple sclerosis is an autoimmune demyelinating disease of the CNS affecting approximately 2.8 million people globally. Spasticity (muscle stiffness and spasms) affects 60–80% of MS patients and is a major source of disability and pain. Conventional antispasticity drugs (baclofen, tizanidine) provide incomplete relief and have significant side effects. Cannabinoids modulate MS symptoms through multiple mechanisms: CB1 receptor activation reduces spasticity by inhibiting excitatory neurotransmitter release in spinal motor circuits; CB2 receptor activation on microglia reduces neuroinflammation; and combined THC:CBD may have neuroprotective effects. The pivotal CAMS (Cannabinoids in Multiple Sclerosis) trial (2003) and subsequent MUSEC trial (2012) established nabiximols' efficacy for spasticity. A 2014 Cochrane review of 12 RCTs found moderate evidence for cannabinoids in MS spasticity. Nabiximols is not FDA-approved in the US, where it remains under investigation. Beyond spasticity, cannabinoids show evidence for MS-related neuropathic pain, bladder dysfunction (urinary urgency and frequency), and sleep disturbance.
Evidence summary for cannabinoid-based interventions in Multiple Sclerosis.
Mechanism: THC:CBD 1:1 ratio activates CB1 receptors in spinal motor circuits (reducing spasticity) and CB2 receptors on microglia (reducing neuroinflammation); CBD moderates THC psychoactivity
Clinical Status: Approved in 30+ countries (Canada, UK, EU) for MS spasticity; not FDA-approved in US
Each spray delivers 2.7mg THC + 2.5mg CBD. Titrated over 2 weeks. Most studied cannabinoid formulation for MS. Adverse effects include dizziness, fatigue, and cognitive effects. Responder analysis: ~50% of patients achieve ≥20% spasticity reduction.
Mechanism: CB1 agonism reduces spasticity and neuropathic pain; suppresses bladder detrusor overactivity
Clinical Status: Multiple RCTs; used off-label in some jurisdictions
Oral THC (dronabinol) and inhaled cannabis have been studied in MS. Psychoactive effects limit tolerability. Bladder dysfunction evidence is particularly promising.
Mechanism: Anti-inflammatory via CB2 receptors; potential neuroprotective effects; may reduce neuroinflammation in MS lesions
Clinical Status: Limited RCT evidence for MS specifically; ongoing trials
CBD alone has less evidence for MS than nabiximols. May contribute to nabiximols' efficacy. Potential neuroprotective effects in MS models are under investigation.
Peer-reviewed research on cannabinoids and Multiple Sclerosis.
Zajicek J, Fox P, Sanders H, et al. · The Lancet
Largest MS cannabinoid trial (630 patients). Oral cannabis extract and THC did not significantly reduce Ashworth spasticity scores vs. placebo, but patient-reported spasticity, pain, and sleep significantly improved.
View on DOI.orgCollin C, Davies P, Mutiboko IK, et al. · European Journal of Neurology
Nabiximols significantly reduced patient-reported spasticity (NRS) vs. placebo in MS patients with treatment-resistant spasticity. Responder rate: 40% vs. 22% placebo.
View on DOI.orgWhiting PF, Wolff RF, Deshpande S, et al. · Cochrane Database of Systematic Reviews
Cochrane review of 12 RCTs found moderate evidence for cannabinoids improving patient-reported spasticity and neuropathic pain in MS. Adverse effects were common but generally mild.
View on DOI.orgNabiximols (Sativex) is not FDA-approved in the US. It is approved in Canada, the UK, and most EU countries for MS-related spasticity. In the US, it is available only through clinical trials. Patients in the US may access medical cannabis through state programs.
Evidence for cannabis and MS fatigue is mixed. Some studies show improvement in fatigue with cannabinoids; others show no effect or worsening. THC can cause fatigue as a side effect. CBD may have mild energizing effects at low doses. Fatigue is not a primary indication for cannabinoid treatment in MS.
There is no clinical evidence that cannabis slows MS progression. Preclinical studies suggest cannabinoids may have neuroprotective and anti-inflammatory effects relevant to MS, but no clinical trial has demonstrated disease-modifying effects. Cannabis is used for symptom management, not disease modification.
Yes — there is emerging evidence that cannabinoids reduce urinary urgency and frequency in MS. THC suppresses bladder detrusor overactivity via CB1 receptors. Nabiximols has shown bladder benefits in some trials. This is an active area of research.
